125 related articles for article (PubMed ID: 20028380)
1. JTE-607, a multiple cytokine production inhibitor, induces apoptosis accompanied by an increase in p21waf1/cip1 in acute myelogenous leukemia cells.
Tajima N; Fukui K; Uesato N; Maruhashi J; Yoshida T; Watanabe Y; Tojo A
Cancer Sci; 2010 Mar; 101(3):774-81. PubMed ID: 20028380
[TBL] [Abstract][Full Text] [Related]
2. JTE-607, a multiple cytokine production inhibitor, ameliorates disease in a SCID mouse xenograft acute myeloid leukemia model.
Uesato N; Fukui K; Maruhashi J; Tojo A; Tajima N
Exp Hematol; 2006 Oct; 34(10):1385-92. PubMed ID: 16982331
[TBL] [Abstract][Full Text] [Related]
3. JTE-607, a novel inflammatory cytokine synthesis inhibitor without immunosuppression, protects from endotoxin shock in mice.
Kakutani M; Takeuchi K; Waga I; Iwamura H; Wakitani K
Inflamm Res; 1999 Aug; 48(8):461-8. PubMed ID: 10493164
[TBL] [Abstract][Full Text] [Related]
4. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.
Yu Z; Du J; Hui H; Kan S; Huo T; Zhao K; Wu T; Guo Q; Lu N
Theranostics; 2021; 11(1):93-106. PubMed ID: 33391463
[No Abstract] [Full Text] [Related]
5. JTE-607, a multiple cytokine production inhibitor, targets CPSF3 and inhibits pre-mRNA processing.
Kakegawa J; Sakane N; Suzuki K; Yoshida T
Biochem Biophys Res Commun; 2019 Oct; 518(1):32-37. PubMed ID: 31399191
[TBL] [Abstract][Full Text] [Related]
6. The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia.
Nakamura S; Hirano I; Okinaka K; Takemura T; Yokota D; Ono T; Shigeno K; Shibata K; Fujisawa S; Ohnishi K
Carcinogenesis; 2010 Nov; 31(11):2012-21. PubMed ID: 20823107
[TBL] [Abstract][Full Text] [Related]
7. High levels of constitutive WAF1/Cip1 protein are associated with chemoresistance in acute myelogenous leukemia.
Zhang W; Kornblau SM; Kobayashi T; Gambel A; Claxton D; Deisseroth AB
Clin Cancer Res; 1995 Sep; 1(9):1051-7. PubMed ID: 9816079
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.
Weisberg E; Halilovic E; Cooke VG; Nonami A; Ren T; Sanda T; Simkin I; Yuan J; Antonakos B; Barys L; Ito M; Stone R; Galinsky I; Cowens K; Nelson E; Sattler M; Jeay S; Wuerthner JU; McDonough SM; Wiesmann M; Griffin JD
Mol Cancer Ther; 2015 Oct; 14(10):2249-59. PubMed ID: 26206331
[TBL] [Abstract][Full Text] [Related]
9. Anti-Tumor and Immune Enhancing Activities of Rice Bran Gramisterol on Acute Myelogenous Leukemia.
Somintara S; Leardkamolkarn V; Suttiarporn P; Mahatheeranont S
PLoS One; 2016; 11(1):e0146869. PubMed ID: 26752299
[TBL] [Abstract][Full Text] [Related]
10. IL-1β inhibits self-renewal capacity of dormant CD34⁺/CD38⁻ acute myelogenous leukemia cells in vitro and in vivo.
Yang J; Ikezoe T; Nishioka C; Nobumoto A; Yokoyama A
Int J Cancer; 2013 Oct; 133(8):1967-81. PubMed ID: 23564444
[TBL] [Abstract][Full Text] [Related]
11. Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors.
Heo SK; Noh EK; Gwon GD; Kim JY; Jo JC; Choi Y; Koh S; Baek JH; Min YJ; Kim H
Eur J Pharmacol; 2016 Oct; 789():280-290. PubMed ID: 27477352
[TBL] [Abstract][Full Text] [Related]
12. Meisoindigo is a promising agent with in vitro and in vivo activity against human acute myeloid leukemia.
Lee CC; Lin CP; Lee YL; Wang GC; Cheng YC; Liu HE
Leuk Lymphoma; 2010 May; 51(5):897-905. PubMed ID: 20233051
[TBL] [Abstract][Full Text] [Related]
13. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
14. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.
Rao J; Xu DR; Zheng FM; Long ZJ; Huang SS; Wu X; Zhou WH; Huang RW; Liu Q
J Transl Med; 2011 May; 9():71. PubMed ID: 21595920
[TBL] [Abstract][Full Text] [Related]
15. Effects of a cytokine inhibitor, JTE-607, on the response to endotoxin in healthy human volunteers.
Borozdenkova S; Mant TG; Allen E; Pu K; Hoshino S; Jurcevic S
Int Immunopharmacol; 2011 Nov; 11(11):1837-43. PubMed ID: 21820084
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic effect of JTE-607 on LPS-induced acute lung injury in rats with CINC-1 inhibition.
Iwamura H; Inushima K; Takeuchi K; Kakutani M; Wakitani K
Inflamm Res; 2002 Mar; 51(3):160-6. PubMed ID: 12005207
[TBL] [Abstract][Full Text] [Related]
17. N-ras oncogene-induced gene expression in human hematopoietic progenitor cells: upregulation of p16INK4a and p21CIP1/WAF1 correlates with myeloid differentiation.
Shen S; Passioura T; Symonds G; Dolnikov A
Exp Hematol; 2007 Jun; 35(6):908-19. PubMed ID: 17533045
[TBL] [Abstract][Full Text] [Related]
18. Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax.
Gaur T; Poddutoori R; Khare L; Bagal B; Rashmi S; Patkar N; Tembhare P; Pg S; Shetty D; Dutt A; Zhang Q; Konopleva M; Platzbeckar U; Gupta S; Samajdar S; Ramchandra M; Khattry N; Hasan SK
J Exp Clin Cancer Res; 2023 Jul; 42(1):186. PubMed ID: 37507802
[TBL] [Abstract][Full Text] [Related]
19. Induction of G2/M Cell Cycle Arrest via p38/p21
Pai JT; Hsu MW; Leu YL; Chang KT; Weng MS
Molecules; 2021 Aug; 26(17):. PubMed ID: 34500594
[TBL] [Abstract][Full Text] [Related]
20. Cytoprotective effects of hematopoietic growth factors on primary human acute myeloid leukemias are not mediated through changes in BCL-2, bax, or p21WAF1/CIP1.
DiGiuseppe JA; Kastan MB; Weng LJ; Gore SD
In Vivo; 1999; 13(1):1-6. PubMed ID: 10218124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
